A phase III trial presented at ESMO 2025 shows that combining enzalutamide with hormone therapy (ADT) cuts the risk of death by over 40% in men with advanced prostate cancer that returns after surgery or radiation. The EMBARK trial, involving 1,068 men, tested enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy in high-risk, biochemically recurrent […]